I’m surprised that they are publishing a protocol this far into the game, but I expect there are interesting tidbits:
Test of Rapamycin in Aging Dogs (TRIAD): study design and rationale for a prospective, parallel-group, double-masked, randomized, placebo-controlled, multicenter trial of rapamycin in healthy middle-aged dogs from the Dog Aging Project.
Coleman AE, Creevy KE, Anderson R, Reed MJ, Fajt VR, Aicher KM, Atiee G, Barnett BG, Baumwart RD, Boudreau B, Cunningham SM, Dunbar MD, Ditzler B, Ferguson AM, Forsyth KK, Gambino AN, Gordon SG, Hammond HK, Holland SN, Iannaccone MK, Illing K, Kadotani S, Knowles SA, MacLean EL, Maran BA, Markovic LE, McGrath S, Melvin RL, Mueller MS, Nelson OL, Olby NJ, Pancotto TE, Parsley E, Potter BM, Prescott JO, Saunders AB, Sawyer HM, Scansen BA, Schmid SM, Smith CC, Tjostheim SS, Tolbert MK, Tropf MA, Visser LC, Ward JL, Wesselowski SR, Windsor RC, Yang VK, Ruple A, Promislow DEL, Kaeberlein M; Dog Aging Project Consortium.
Geroscience. 2025 Feb 14. doi: 10.1007/s11357-024-01484-7. Epub ahead of print. PMID: 39951177.
… The Test of Rapamycin In Aging Dogs (TRIAD) randomized clinical trial is a parallel-group, double-masked, randomized, placebo-controlled, multicenter trial that will test the ability of rapamycin to prolong lifespan and improve several healthspan metrics in healthy, middle-aged dogs recruited from Dog Aging Project participants. Here, we describe the rationale, design, and goals of the TRIAD randomized clinical trial, the first rigorous test of a pharmacologic intervention against biological aging with lifespan and healthspan metrics as endpoints to be performed outside of the laboratory in any species.
4 Likes
I have the paper, but promised the author I wouldn’t share it its entirety. Here are some tidbits:
3 Likes
For those interested… TriumVet’s patent on their formulation of rapamycin for pets:
2 Likes
I find this interesting… half life, comparison in dogs. The “Reference Standard” is rapamune:
1 Like
This sounds brilliant. Finally a properly designed study which will use a good dose, with a proper formulation. Stratifying by body weight is a great move, but using whole coated tablets is going to be important. So the way they’ve approached this is very smart IMO. No stupid compound pharmacy formulations.
They also seem to be collecting a ton of parameters, and not just biomarkers but actual cognitive and physical functional tests.
I just hope that if there is an effect, it’s large enough to be measured with this relatively small-ish sample size, since I imagine there’s a lot of variability within each group. Of course, that’s also a strength of the trial because it reflects the lifestyle and environment of the owners. However, it’s inherently noisier than a cage of identical mice!
Do you have any information about the current status, and when it might publish results?
2 Likes
